Sagimet Biosciences Inc.
Fatty acid synthase (FASN) inhibitors—small molecule therapeutics targeting metabolic and fibrotic pathways
New patent ·
- Sector
- Biotech
- Headquarters
- SAN MATEO, CA
- Founded
- 2006
- Latest Form D
- $69M, Jan 2021
- Total capital
- $158M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $158M
- 7 Form D · last Jan 2021
- 70 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 21 pending · first 2021
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$69M
- Private capital raisedForm D · SEC · 6th filing$35.2M
- Private capital raisedForm D · SEC · 5th filing$5.4M
- Private capital raisedForm D · SEC · 4th filing$14.3M
- Private capital raisedForm D · SEC · 3rd filing$7.5M
- Private capital raisedForm D · SEC · 2nd filing$12M
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Beth SeidenbergDirectorNamed in SEC Form D filings
- Dennis HomExecutive OfficerNamed in SEC Form D filings
- George KembleExecutive Officer, DirectorNamed in SEC Form D filings
- Gordon RingoldDirectorNamed in SEC Form D filings
- James YoungDirectorNamed in SEC Form D filings
- Jason FullerDirectorNamed in SEC Form D filings
Show all 9 people
- Jinzi Jason WuDirectorNamed in SEC Form D filings
- Merdad ParseyDirectorNamed in SEC Form D filings
- Richard RodgersDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 25- New patentCombination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsUSPTOUS 12,746,242
- PendingCombination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsUSPTOApplication 19228638
- GrantedHeterocyclic Modulators Of Lipid SynthesisUSPTOUS 12,551,490
Show all 25 patent records
- Combination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsSep 29, 2026 · US 12,746,242Granted
- Combination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsFeb 19, 2026 · Application 19228638Pending
- Heterocyclic Modulators Of Lipid SynthesisFeb 17, 2026 · US 12,551,490Granted
- Methods For Prediction Of Treatment Response In Non-alcoholic Fatty Liver DiseaseMay 22, 2025 · Application 18709271Pending
- Combination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsJan 16, 2025 · Application 18749069Pending
- Heterocyclic Modulators Of Lipid SynthesisDec 5, 2024 · Application 18535291Pending
- Heterocyclic Modulators Of Lipid SynthesisApr 11, 2023 · US 11,622,968Granted
- Heterocyclic Modulators Of Lipid SynthesisOct 27, 2022 · Application 17307985Pending
- Heterocyclic Modulators Of Lipid SynthesisJun 15, 2021 · US 11,034,690Granted
- Combination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsApplication 63509267Pending
- Methods For Prediction Of Treatment Response In Non-alcoholic Fatty Liver DiseaseApplication PCTUS2022049566Pending
- Methods For Prediction Of Treatment Response In Non-alcoholic Fatty Liver DiseaseApplication 63417970Pending
- Methods For Prediction Of Treatment Response In Non-alcoholic Fatty Liver DiseaseApplication 63278298Pending
- Methods Of Treating NashApplication 19607988Pending
- Combinations Of Fasn Inhibitors And GLP-1 Agonists For Liver DiseasesApplication 19527665Pending
- Industrial Preparation Of Heterocyclic Modulator For Lipid SynthesisApplication 19490670Pending
- Pharmaceutical Composition Containing Heterocyclic CompoundApplication 19504289Pending
- Methods Of Treating NashApplication 63721480Pending
- Methods Of Treating NashApplication PCTUS2025012416Pending
- Combinations Of Fasn Inhibitors And GLP-1 Agonists For Liver DiseasesApplication PCTUS2024050752Pending
- Combination Therapies Of Fasn Inhibitors With Thyroid Hormone Receptor AgonistsApplication PCTUS2024034827Pending
- Methods Of Treating NashApplication 63623515Pending
- Combinations Of Fasn Inhibitors And GLP-1 Agonists For Liver DiseasesApplication 63623511Pending
- Methods Of Treating NashApplication 63623311Pending
- Combinations Of Fasn Inhibitors And GLP-1 Agonists For Liver DiseasesApplication 63589280Pending
Related companies, and why
- DalCor Pharmaceuticals US, LLCSimilar federal contract value in Biotech · null in contracts
- AMARIN CORP PLC\UKSimilar federal contract value in Biotech · null in contracts
- KIORA PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Scienture Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Aloe Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MYOGENICA INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .